Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTSO Cytosorbents	$1.16 -3.3%	$0.98	$0.70 ▼ $1.61	$72.63M	1.05	147,312 shs	44,051 shs
INO Inovio Pharmaceuticals	$1.95 +2.6%	$1.95	$1.42 ▼ $12.33	$71.51M	1.34	626,628 shs	560,050 shs
NSPR InspireMD	$2.42 +0.4%	$2.49	$2.07 ▼ $3.80	$74.14M	0.59	39,608 shs	23,164 shs
NXGL NexGel	$2.41 -3.6%	$2.47	$1.84 ▼ $5.10	$18.45M	0.52	70,425 shs	23,219 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTSO Cytosorbents	-3.33%	+6.42%	+36.45%	+6.42%	+54.05%
INO Inovio Pharmaceuticals	+2.63%	-8.02%	-5.80%	+0.52%	-77.22%
NSPR InspireMD	+0.41%	-1.22%	+7.08%	-12.00%	-12.64%
NXGL NexGel	-3.60%	+0.84%	+0.84%	-9.40%	+9.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTSO Cytosorbents	1.7053 of 5 stars	3.5	2.0	0.0	1.8	0.0	0.6
INO Inovio Pharmaceuticals	3.6805 of 5 stars	3.3	2.0	4.3	2.8	0.0	0.6
NSPR InspireMD	2.5365 of 5 stars	3.5	2.0	0.0	2.1	2.5	0.6
NXGL NexGel	0.9904 of 5 stars	0.0	5.0	0.0	1.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTSO Cytosorbents	3.00	Buy	$5.50	374.14% Upside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	400.00% Upside
NSPR InspireMD	3.00	Buy	$4.50	85.95% Upside
NXGL NexGel	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NXGL, CTSO, NSPR, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	CTSO Cytosorbents	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.00 ➝ $1.00
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
5/12/2025	NSPR InspireMD	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.50 ➝ $4.00
5/2/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/3/2025	CTSO Cytosorbents	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.00 ➝ $1.00
4/1/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/19/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$6.00 ➝ $5.00
3/19/2025	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTSO Cytosorbents	$35.60M	2.04	N/A	N/A	$0.20 per share	5.80
INO Inovio Pharmaceuticals	$220K	325.03	N/A	N/A	$1.90 per share	1.03
NSPR InspireMD	$7.03M	10.55	N/A	N/A	$1.83 per share	1.32
NXGL NexGel	$10.23M	1.80	N/A	N/A	$0.90 per share	2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTSO Cytosorbents	-$20.72M	-$0.28	N/A	N/A	N/A	-41.77%	-105.04%	-29.18%	8/12/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
NSPR InspireMD	-$19.92M	-$0.79	N/A	N/A	N/A	-413.96%	-69.42%	-57.68%	N/A
NXGL NexGel	-$3.28M	-$0.45	N/A	∞	N/A	-30.80%	-54.95%	-27.84%	N/A

Latest NXGL, CTSO, NSPR, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CTSO Cytosorbents	-$0.08	-$0.06	+$0.02	-$0.02	$9.01 million	$8.73 million
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/13/2025	Q1 2025	NXGL NexGel	-$0.10	-$0.09	+$0.01	-$0.09	$2.73 million	$2.81 million
3/31/2025	Q4 2024	CTSO Cytosorbents	-$0.07	-$0.03	+$0.04	-$0.14	$10.09 million	$9.20 million
3/24/2025	Q4 2024	NXGL NexGel	-$0.10	-$0.08	+$0.02	-$0.11	$2.99 million	$3.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTSO Cytosorbents	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NSPR InspireMD	N/A	N/A	N/A	N/A	N/A
NXGL NexGel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTSO Cytosorbents	0.98	2.61	2.30
INO Inovio Pharmaceuticals	N/A	2.63	2.63
NSPR InspireMD	N/A	6.39	6.05
NXGL NexGel	0.15	1.88	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTSO Cytosorbents	32.87%
INO Inovio Pharmaceuticals	26.79%
NSPR InspireMD	44.78%
NXGL NexGel	2.21%

Insider Ownership

Company	Insider Ownership
CTSO Cytosorbents	7.30%
INO Inovio Pharmaceuticals	2.30%
NSPR InspireMD	34.06%
NXGL NexGel	20.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTSO Cytosorbents	220	62.61 million	58.04 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
NSPR InspireMD	50	30.64 million	18.33 million	Optionable
NXGL NexGel	10	7.66 million	6.08 million	Not Optionable

NXGL, CTSO, NSPR, and INO Headlines

Recent News About These Companies

NEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2nd

May 21, 2025 | finance.yahoo.com

Earnings call transcript: Nexgel’s Q1 2025 results show growth, future optimism

May 15, 2025 | uk.investing.com

NEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

NEXGEL Reports First Quarter 2025 Financial Results

May 13, 2025 | taiwannews.com.tw

1NXGL : A Peek at NexGel's Future Earnings

May 12, 2025 | benzinga.com

NEXGEL to Announce Q1 2025 Financial Results on May 13

May 12, 2025 | msn.com

NEXGEL, Inc. to Release First Quarter 2025 Financial Results and Host Conference Call on May 13, 2025

May 9, 2025 | quiverquant.com

NEXGEL to Report First Quarter 2025 Financial Results on May 13th

May 9, 2025 | globenewswire.com

NEXGEL CEO Adam Levy to Present at Planet MicroCap Showcase 2025

April 9, 2025 | msn.com

NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24th

April 7, 2025 | markets.businessinsider.com

Adam R. Levy Sells 4,000 Shares of NEXGEL, Inc. (NASDAQ:NXGL) Stock

April 3, 2025 | insidertrades.com

NEXGEL Reports Record-Breaking 2024 Financial Performance

March 27, 2025 | msn.com

NEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Call Transcript

March 26, 2025 | insidermonkey.com

Earnings call transcript: Nexgel Q4 2024 sees revenue surge, stock jumps

March 26, 2025 | investing.com

NEXGEL, Inc. Reports Record Q4 and Full Year 2024 Revenue Growth of 181% and 112% Respectively, Forecasts $13 Million in Revenue for 2025

March 26, 2025 | nasdaq.com

NEXGEL Reports Record Revenue Growth in 2024

March 25, 2025 | tipranks.com

NEXGEL targets $13M revenue in 2025 amid product and partnership expansion

March 24, 2025 | msn.com

NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript

March 24, 2025 | seekingalpha.com

NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results

March 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXGL, CTSO, NSPR, and INO Company Descriptions

Cytosorbents NASDAQ:CTSO

$1.16 -0.04 (-3.33%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.11 -0.05 (-4.66%)

As of 06/18/2025 07:50 PM Eastern

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Inovio Pharmaceuticals NASDAQ:INO

$1.95 +0.05 (+2.63%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.02 (+1.03%)

As of 06/18/2025 07:51 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

InspireMD NYSE:NSPR

$2.42 +0.01 (+0.41%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.42 0.00 (-0.21%)

As of 06/18/2025 04:04 PM Eastern

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

NexGel NASDAQ:NXGL

$2.41 -0.09 (-3.60%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.44 +0.03 (+1.45%)

As of 06/18/2025 06:14 PM Eastern

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time